Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Rectal Neoplasms 11Esophageal Neoplasms 11Pancreatic Neoplasms 7Cholangiocarcinoma 6Liver Neoplasms 5Colonic Neoplasms 4Neoplasms 3Colorectal Cancer Metastatic 3Spinocerebellar Degenerations 2Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Liver Diseases 2Gastric Adenocarcinoma 2Advanced Biliary Tract Cancer 2Uterine Cervical Neoplasms 1Unresectable Locally Advanced Pancreatic Cancer 1Turcot syndrome 1Tislelizumab 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1PD-1 Antibody 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Microsatellite Stable Metastatic Colorectal Cancer 1

Interventions

Gemcitabine 113Cisplatin 77Oxaliplatin 46pembrolizumab 35Fluorouracil 33Capecitabine 31durvalumab 27Leucovorin 27lenvatinib 26Magnetic Resonance Spectroscopy 15Irinotecan 14Drug Therapy 13Biopsy 13Nivolumab 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Platinum 8Photochemotherapy 8Liver Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Cholangiocarcinoma × sintilimab × Gastrointestinal × Clear all
NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Zhongda Hospital

Phase 2 Completed
25 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Fudan University

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05010668 2025-02-21

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Fudan University

Phase 2 Completed
28 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Unknown
30 enrolled
Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma

NCT05251662 2022-02-23

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
90 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05207735 2022-01-26

SCRCA

Henan Cancer Hospital

Phase 2 Unknown
73 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡